The human cell atlas (HCA) had its inaugural planning meeting in London, in October 2016, organized by Dr S. Teichmann (Wellcome Trust Sanger Institute) and Dr A. Regev (Broad Institute of MIT and Harvard) and has triggered widespread excitement with its ambitious goals. The HCA aims to describe and define the complete cellular landscape of the human body (https://www.humancellatlas.org/). 1 By analogy to the Human Genome Project, the HCA aims to map cells of the human body integrating single-cell and spatial transcriptomics, moving well beyond purely descriptive features and guiding functional studies towards the identification of previously unrecognized subtleties in disease. With a collegial and synergizing approach, the HCA recognizes that its success depends on a global effort, because of the complexity and size of the project. A globally concerted effort will enable the replication and coordination of technologies in independent laboratories and, importantly, .pdf) to share the outline and structure of the initiative, describe the available technology for data acquisition and analysis and introduce the framework of the Data Coordination Platform. The latter is the key infrastructure and virtual space where researchers from around the world input data on a synchronized store with multiple cloud copies, it also includes pipelines for basic data processing as well as tertiary portals for next level of analysis and visualization, the whole with an open access output. A first pre-release with data from thousands of single cells is available for a number of organs and systems but, not yet, for any cardiovascular specific dataset (https://preview.data.humancellatlas.org/).
The sine qua non to conceive a project of this scale was the development and widespread access of two new technologies: cost-efficient highthroughput single-cell RNA sequencing and spatial transcriptomics. 2, 3 Until now, we have largely been phenotyping tissues using bulk cells or methods such as immunohistology with low resolution: unsurprising, functional discrepancies are common between studies. Now single cell transcriptomics provide information of prevalence, heterogeneity and co-expression at the individual cell level, generating a new outlook for intracellular and intercellular pathway definition, otherwise masked by bulk analysis. 4, 5 Feasibility and, more importantly, sensitivity and specificity of single cell transcriptomics was proven on developing and adult mouse hearts, including in the recent compendium of single cell transcriptomics data (100 000 cells from 20 organs and tissues), reported by the Tabula Muris consortium. [6] [7] [8] [9] These studies revealed unanticipated cell diversity and previously unknown cell-to-cell interactions, which together with spatiotemporal transcriptomics of heart development exposed lineagespecific gene programmes in normal cardiac development and in a congenital heart disease model. 7, 8 In a mouse model of cardiac fibrosis, definition of co-expression patterns at the single cell level allowed to pinpoint disease associated gene expression changes and define an autocrine loop mediated by IL11/IL11RA that triggers a fibrotic response in the adult cardiac fibroblasts. 10 Crucially, spatial resolution proved to be essential in the identification of SOX9 as a key regulator of cardiac fibrosis in a mouse model of ischaemic injury. 11 Indeed, spatial transcriptomic adds another dimension, permitting identification of the location of specific cells, and their transcripts by overlaying haematoxylin and eosin stained sections onto microarrays spotted with 100 lm barcoded topographies. 2 The HCA's plan to integrate these two leading-edge technologies is key for at least three fundamental aspects that are far beyond a mere descriptive approach: defining the histological and anatomical localization of newly identified cell types and/or functional states; outlining precise and specific cellto-cell interactions including autocrine and paracrine pathways; and understanding lineage decisions with topographical and functional insights. Beyond the immense technological advancement of these highresolution techniques coupled with high-throughput sequencing, bioinformatics analysis is the propeller and key step to process and mine the data. Computational biology requires close integration and interaction of biological and clinical experts, from the initial experimental design, through a dynamic and continued assessment of data generation and results, via a number of iterations, finally to reach solid conclusions of any spatial and single cell resolution study.
The HCA vision includes the compiling of a development dataset: the project therefore answers the need, not only for a cardiovascular adult atlas, but also for a developmental one. Certainly, whole heart analysis of the earliest available stages is a priority: to understand the normal dynamics of development; gain mechanistic inferences in cardiac congenital malformations at the level of specific cellular transitions; and discern functional pathways driving lineage decisions and differentiation towards post-natal functional cells. Although cell dissociation is more feasible during development, with fewer of the tissue disaggregation challenges specific to the adult tissue, tissue acquisition in both cases remains an issue requiring further discussion beyond the scope of this commentary. Nevertheless, new technical approaches including single nuclei sequencing (which can utilize frozen samples) have enabled researchers to overcome some of these apparent difficulties and identify, for example, a specific lincRNA-regulated stress response in mouse and human cardiomyocytes. 12 In line with the aim of a human cardiovascular cell atlas, a huge goal with a correspondingly game-changing impact would be to reconstruct cell-by-cell the entire vasculature branching from the heart, revealing a roadmap of vascular cell heterogeneities and the corresponding variation of cellular interactions with each organ's specialized function. 13, 14 As a whole, the HCA will provide novel and unbiased insights into cardiovascular cell biology of the healthy and diseased heart including: cardiomyocyte heterogeneities in proliferative and differentiation status; the effect of chamber specificity; potentially more subtle diversities between epicardial-endocardial fronts; identification of human cardiac and vascular stem/progenitor cells; endothelial, smooth muscle cells, and pericytes heterogeneities from microvasculature to larger blood vessels, including lymphatics; heterogeneity of cardiac mesenchymal cells and fibroblasts; the cardiac immune cell repertoire; and cardiac neuronal cells in the heart. In this scenario, the definition of heterogeneity, prevalence and spatial distribution of cells and/or marker genes within their lineage relationships will provide the key points to infer and then validate dynamic processes underlying developmental trajectories and to investigate how cells communicate within their tissue microenvironment.
With estimated 37.2 trillion cells in the human body, even to map every cell of the adult heart alone might take a number of years. However, high resolution maps in strategic anatomical regions of the healthy heart and vasculature will provide immediate invaluable information, especially, when compared with diseased samples. In addition, subsequent iterations integrated with machine learning and artificial intelligence approaches will surely and gradually fill in the gaps and, eventually, provide a few new volumes of textbook anatomy. The data generated will bring a completely new perspective, emerging from single cells transcriptomics, going beyond the single cell boundaries to their interactome and re-building tissue architecture with novel mechanistic insights.
Using the freely available data, a joint effort between the HCA and the broad cardiovascular community of biologists and clinicians will contribute to changes in diagnosis and prognosis; monitoring disease states to observe shifts in cell types or states and the emergence of novel biomarkers. 15 Thus, not only the level of resolution of clinical parameters will increase with cell specificity but also the quantity and quality of information, including frequency and co-expression, will allow to capture nuances of disease. The new information will contribute to more specific diagnosis, staging, ability to monitor the response to therapy but also disclose novel therapeutic targets, previously masked by bulk analysis and limited capacity to analyse many markers in the same cells. To find out more, or join this initiative as a contributor or data user, go to https://www.humancellatlas.org/joinHCA. 
